NCT04661280招募中3 期
Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Difference of change in the MMSE score
研究概览
简要总结
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.
The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.
详细描述
Randomized multicentric open-label study, comparison of 2 therapeutic strategies.
2 arms:
- Standard of care, non-drug approach: following the recommendations of the Alzheimer's disease care by the Frenchh Health Authority. The care is cognitive, psychic, functional or social and centered on the patient and his environment. This care is best carried out by the memory consultations participating in this study and having extensive experience in the care of Alzheimer patients. It is usually based in particular on the prescription of cognitive stimulation sessions by a speech therapist and a mobile Alzheimer specialist team at home for cognitive remediation sessions.
- Donepezil group: Management similar to the previous arm plus addition of Donepezil 5 mg per os once a day for one month and then 10 mg per os once a day until the 6th month.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Alzheimer's disease according to the IWG-2 criteria.
- •Age ≥ 50 years.
- •Absence of legal protection measures (guardianship, curatorship).
- •MMSE score ≥ 10 at inclusion.
- •abnormal values for Aβ42 in the CSF or Aβ40 / Aβ42 ratio.
- •abnormal values for phosphorylated Tau in CSF
- •Presence of a family carer or a person at home who can ensure compliance with treatment if MMSE score <
- •French native speaker.
排除标准
- •Other cause of dementia.
- •Previous use of symptomatic treatment for Alzheimer's disease.
- •Hypersensitivity to donepezil hydrochloride or to any of the excipients listed in the SPC.
- •Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, sinus disease or other supra-ventricular conduction abnormalities such as sinoatrial or atrioventricular block.
- •Taking concomitant medications known to prolong the interval QTc
- •Patients at particular risk of ulcer, known ulcer disease or receiving concomitant treatment with non-steroidal anti-inflammatory drugs.
- •Patient at risk of urinary retention.
- •History of epileptic disease.
- •History of neuroleptic malignant syndrome.
- •History of asthma or obstructive bronchopulmonary disease.
- •Severe hepatic impairment.
- •Taking one of the following treatments:
- •CYP3A4 inhibitors, such as ketonazole.
- •2D6 inhibitors, such as quinidine.
- •CYP3A4 inhibitors, such as itraconazole and erythromycin.
- •CYP2D6 inhibitors, such as fluoxetine.
- •Enzyme inducers such as rifampicin, phenytoin, carbamazepine.
- •Antiarrhythmic class IA agents
- •Antiarrhythmic class III agents
- •other Antipsychotics such as phenothiazine, sertindole, pimozide, ziprasidone.
- •some antiobiotics such as clarithromycine, erythromycine, levofloxacine, moxifloxacine.
- •Participation in another interventional study.
研究组 & 干预措施
Cognitive remediation + Donepezil
Experimental
Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
干预措施: Donepezil (Drug)
Cognitive remediation
No Intervention
Non-drug treatment, cognitive remediation, cognitive stimulation
结局指标
主要结局
Difference of change in the MMSE score
时间窗: 26 weeks
Difference of change in the MMSE score between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). MMSE is measured at baseline, 6 weeks, 13 weeks, and 26 weeks.
次要结局
- Difference of change in the ADAS-Cog scale(26 weeks)
- Difference of change in the ZARIT scale(26 weeks)
- Difference of change in the CDR scale(26 weeks)
- Difference of change in the ADL scale(26 weeks)
- Difference of change in the quality of life scale(26 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease: CHOLINE-2 studyEUCTR2021-001788-26-FRAssistance Publique - Hôpitaux de Paris120
尚未招募
不适用
Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer DiseaseNCT05114499First Affiliated Hospital Xi'an Jiaotong University150
已完成
1 期
Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical DevelopmentAlzheimer DiseaseBatteryNCT01487395University Hospital, Lille30
招募中
不适用
Discontinuation of antidementia medication in extremely severe dementia patients: a 12-week randomized multicenter trialDiseases of the nervous systemKCT0000874Bobath Memorial Hospital120
进行中（未招募）
1 期
Dopaminergic therapy for Alzheimer's disease patientsMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2015-002965-43-ITI.R.C.C.S. FONDAZIONE S.LUCIA130